ProPhase Labs, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Cover
Financial Statements
Notes to Financial Statements
Accounting Policies
- Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Commitments and Contingencies (Details)

v3.24.1.1.u2

Commitments and Contingencies (Details) $ in Thousands		3 Months Ended
Commitments and Contingencies (Details) $ in Thousands	Jul. 19, 2022 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($) investor	Nov. 15, 2022	May 01, 2021 option
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Renewal options \| option					4
Renewal period (in years)				1 year	1 year
Agreement term (in days)					90 days
General and administration		$ 7,593	$ 8,298
Number of sites \| investor			8
Linebacker License Agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront license fee	$ 50
License agreement term (in days)	10 days
License or royalty net revenue percentage	3.00%
Royalty expense	$ 250
Linebacker License Agreements \| Phase 3
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional payment of fee	900
Linebacker License Agreements \| New Drug Application
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional payment of fee	$ 1,000
BE-Smart License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
General and administration		$ 200	$ 200

- Definition

Additional payment of fee.

+ References

No definition available.

+ Details

Name:	prph_AdditionalPaymentOfFee
Namespace Prefix:	prph_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Agreement Term

+ References

No definition available.

+ Details

Name:	prph_AgreementTerm
Namespace Prefix:	prph_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Definition

License Agreement Term

+ References

No definition available.

+ Details

Name:	prph_LicenseAgreementTerm
Namespace Prefix:	prph_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

License Or royalty net revenue percentage.

+ References

No definition available.

+ Details

Name:	prph_LicenseOrRoyaltyNetRevenuePercentage
Namespace Prefix:	prph_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Manufacturing Agreement, Renewal Options

+ References

No definition available.

+ Details

Name:	prph_ManufacturingAgreementRenewalOptions
Namespace Prefix:	prph_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Manufacturing Agreement, Renewal Period

+ References

No definition available.

+ Details

Name:	prph_ManufacturingAgreementRenewalPeriod
Namespace Prefix:	prph_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Definition

Number Of Sites

+ References

No definition available.

+ Details

Name:	prph_NumberOfSites
Namespace Prefix:	prph_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Upfront license fee.

+ References

No definition available.

+ Details

Name:	prph_UpfrontLicenseFee
Namespace Prefix:	prph_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_GeneralAndAdministrativeExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=prph_LinebackerLicenseAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardTypeAxis=prph_PhaseThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardTypeAxis=prph_NewDrugApplicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=prph_BESmartLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: